Investors

Overview

Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company owns a significant intellectual property (IP) portfolio related to DMF formulations. The Company granted to Biogen an irrevocable license to all of its IP through the recent License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 opposition proceeding.


Most Recent Presentation
Download Documentation JMP Securities Life Sciences Conference

Stock Information
FWP (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Financial Status IndicatorC
Price$22.49
Change (%) Stock is Down 0.1 (0.44%)
Volume3,827
Data as of 07/25/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock chart for: FWP.OQ.  Currently trading at $22.49 with a 52 week high of $32.70 and a 52 week low of $14.89.

Recent NewsMore >>
DateTitle 
07/18/17Forward Pharma announces planned distribution of EUR 19.45 per share to Shareholders
COPENHAGEN, Denmark, July 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced plans to return EUR 19.45 per share amounting to a total of EUR 917.7 million to its shareholders through a capital reduction. This decision is based on a careful evaluation of the most appropriate capital allocation strategy after receipt of the non-refundable USD 1.25 billion cash fee from Biogen. The capital reduction aligns the amount of working capital with t... 
Printer Friendly Version
06/14/17Forward Pharma CEO to Present at the JMP Securities 2017 Life Sciences Conference on June 20, 2017
COPENHAGEN, Denmark, June 14, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will present at the JMP Securities 2017 Life Sciences Conference being held June 20-21, 2017 in New York, NY. Dr. Svendsen will present on Tuesday, June 20, at 3:30 PM ET and host one-on-one meetings before and after the presentation. Investors and other interested parties may access a live audio webcast of ou... 
Printer Friendly Version
06/02/17Forward Pharma CEO to Present at the Jefferies 2017 Global Healthcare Conference on June 6, 2017
COPENHAGEN, Denmark, June 02, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference being held June 6-9, 2017 in New York, NY. Dr. Svendsen will present on Tuesday, June 6, at 3:00 PM ET and host one-on-one meetings before and after the presentation. Investors and other interested parties may access a live audio webcast of our ... 
Printer Friendly Version
05/31/17Forward Pharma Appeals the Initial Decision in the U.S. Patent Interference to the Federal Circuit
COPENHAGEN, Denmark, May 31, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing of the notice of appeal of the PTAB decision that ended the interference proceeding between the Forward 11/576,871 patent application (the “’871 application”) and an issued Biogen patent. The appeal was filed to the U.S. Court of Appeals for the Federal Circuit (“Federal Circuit”) and seeks to have the decision overturned and the interference reinstated.... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Forward Pharma A/S posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources